Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results

References

• Drummond MF, Sculpher MJ, Claxton K, et al. Measuring and valuing efffects: health gain. In: Methods for the economic evaluation of health care programmes. 4th ed, Section 5. UK: Oxford university press; 2015.
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE). 7. Assessing cost effectiveness. The guidelines manual PMG6; 2012; Available from: https://www.nice.org.uk/process/pmg6/chapter/assessing-cost-effectiveness. Last accessed on 2019 Apr 04
   Google Scholar
• Haute Autorite de Sante (HAS). Choices in methods for economic evaluation. France: HAS; 2012 [Last accessed on 2019 Apr 04]. Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada. 4th.Canada: CADTH; 2017 [Last accessed on 2019 Apr 04]. Available from: https://www.cadth.ca/dv/guidelines-economic-evaluation-health-technologies-canada-4th-edition
   Google Scholar
• Fukuda T Analysis guidelines for cost-effectiveness evaluation at the central social insurance medical council. 2016.
   Google Scholar
• Zhou J, Millier A, Toumi M. Systematic review of pharmacoeconomic models for schizophrenia. J Mark Access Health Policy. 2018;6:1508272.
   Google Scholar
• Noel CW, Lee DJ, Kong Q, et al. Comparison of health state utility measures in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2015;141:696–11.
   Web of Science ®Google Scholar
• Briggs AH, Belozeroff V, Feeny D. Comparison of health state utility estimates from instrument-based and vignette-based methods: a case study in kidney disease. BMC Res Notes. 2019;12:385.
   Web of Science ®Google Scholar
• Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes. 2008;6:105.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol. 1996;11:101–108.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. NICE Guideline CG178; 2014; Available from: https://www.nice.org.uk/guidance/cg178. Last accessed on 2018 Apr 04
   Google Scholar
• Mavranezouli I. A review and critique of studies reporting utility values for schizophrenia-related health states. Pharmacoeconomics. 2010;28:1109–1121.
   PubMed Web of Science ®Google Scholar
• Németh B, Fasseeh AN, Molnár A, et al. A systematic review of health economic models and utility estimation methods in schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2018. DOI:10.1080/14737167.2018.1430571.
   Web of Science ®Google Scholar
• Hermes ED, Sokoloff D, Stroup TS, et al. Minimum clinically important difference in the positive and negative syndrome scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry. 2012;73:526–532.
   PubMed Web of Science ®Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6:217–227.
   PubMed Web of Science ®Google Scholar
• Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21:402–408.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry. 2014;68:416–427.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Pudas H, Goswami P, et al. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. J Med Econ. 2016;19:111–120.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Pudas H, Zilbershtein R, et al. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. J Med Econ. 2013;16:1096–1105.
   PubMedGoogle Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatr. 2013;25:85–94.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Zilbershtein R, Skoupa J, et al. Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. J Med Econ. 2013;16:1089–1095.
   PubMedGoogle Scholar
• Jukic V, Jakovljevic M, Filipcic I, et al. Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia. Value Health Reg Issues. 2013;2:181–188.
   PubMedGoogle Scholar
• Einarson TR, Bereza BG, Garcia Llinares I, et al. Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain. J Med Econ. 2017;20:1039–1047.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Bereza BG, Tedouri F, et al. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. J Med Econ. 2017;20:1187–1199.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Furiak NM, Lawson AH, et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the USA. J Med Econ. 2012;15:531–547.
   PubMedGoogle Scholar
• Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess. 2003;7:1–193.
   PubMedGoogle Scholar
• Beard SM, Maciver F, Clouth J, et al. A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. Eur J Health Econ. 2006;7:165–172.
   PubMedGoogle Scholar
• Davies A, Vardeva K, Loze JY, et al. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK. Curr Med Res Opin. 2008;24:3275–3285.
   PubMed Web of Science ®Google Scholar
• Dilla T, Moller J, O’Donohoe P, et al. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison. BMC Psychiatry. 2014;14:298.
   PubMed Web of Science ®Google Scholar
• Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France. Pharmacoeconomics. 2016;34:363–391.
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the USA. Cost Eff Resour Alloc. 2009;7:4.
   PubMedGoogle Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the USA: a micro-simulation economic decision model. Curr Med Res Opin. 2011;27:713–730.
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz AJ, Perez-Costillas L, Montesinos AC, et al. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev. 2012;2:8.
   PubMedGoogle Scholar
• Graham CN, Mauskopf JA, Lawson AH, et al. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health. 2012;15:55–64.
   PubMed Web of Science ®Google Scholar
• Greenhalgh J, Knight C, Hind D, et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess. 2005;9:1–156, iii-iv.
   Web of Science ®Google Scholar
• Kasteng F, Eriksson J, Sennfalt K, et al. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2011;124:214–225.
   PubMed Web of Science ®Google Scholar
• Kim B-R-M, Lee T-J, Lee H-J, et al. Cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in South Korea. Value Health Reg Issues. 2012;1:59–65.
   Google Scholar
• Lachaine J, Beauchemin C, Mathurin K, et al. Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada. J Med Econ. 2014;17:296–304.
   PubMedGoogle Scholar
• Lin L, Zhao YJ, Zhou HJ, et al. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. Int Clin Psychopharmacol. 2016;31:84–92.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cragin L, Sorensen S, et al. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract. 2010;16:744–755.
   PubMed Web of Science ®Google Scholar
• Mehnert A, Nicholl D, Pudas H, et al. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ. 2012;15:844–861.
   PubMedGoogle Scholar
• Oh PI, Iskedjian M, Addis A, et al. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol. 2001;8:199–206.
   PubMedGoogle Scholar
• Oh PI, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ. 2001;4:137–156.
   Google Scholar
• Park T, Kuntz KM. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia. Value Health. 2014;17:310–319.
   PubMed Web of Science ®Google Scholar
• Perlis RH, Ganz DA, Avorn J, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005;25:427–434.
   PubMed Web of Science ®Google Scholar
• Wang PS, Ganz DA, Benner JS, et al. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model. J Ment Health Policy Econ. 2004;7:77–85.
   PubMedGoogle Scholar
• Zeidler J, Mahlich J, Greiner W, et al. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Appl Health Econ Health Policy. 2013;11:509–521.
   PubMedGoogle Scholar
• Aigbogun MS, Liu S, Kamat SA, et al. Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. ClinicoEcon. 2018;10:443–456.
   Web of Science ®Google Scholar
• Nuhoho S, Saad A, Saumell G, et al. Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates. Curr Med Res Opin. 2018;34:601–611.
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Trueman D, Crowe L, et al. Cost-utility analysis of lurasidone versus aripiprazole in adults with schizophrenia. Pharmacoeconomics. 2016;34:709–721.
   PubMed Web of Science ®Google Scholar
• Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. Birmingham: University of Birmingham, Department of Public Health and Epidemiology. West Midlands Development and Evaluation Committee Report; 1998.
   Google Scholar
• Glennie JL. Évaluation pharmacoéconomique de la clozapine dans le traitement de la schizophrénie réfractaire et de la rispéridone dans le traitement de la schizophrénie chronique. Ottawa: Office canadien de coordination de l’évaluation des technologies de la santé (OCCETS); 1997.
   Google Scholar
• Konig HH, Gunther OH, Angermeyer MC, et al. Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method. Pharmacoeconomics. 2009;27:405–419.
   PubMed Web of Science ®Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004;71:155–165.
   PubMed Web of Science ®Google Scholar
• Osborne RH, Dalton A, Hertel J, et al. Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study. Health Qual Life Outcomes. 2012;10:35.
   PubMed Web of Science ®Google Scholar
• Seong S, Choi C, Sung Y, et al. Health-related quality of life using EQ-5D in Koreans. J Korean Rheumatol Assoc. 2004;11:254–262.
   Google Scholar
• Ulfsdotter M, Lindberg L, Mansdotter A. A cost-effectiveness analysis of the Swedish universal parenting program all children in focus. PLoS One. 2015;10:e0145201.
   Web of Science ®Google Scholar
• Frederix GW, van Hasselt JG, Schellens JH, et al. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. Pharmacoeconomics. 2014;32:47–61.
   Web of Science ®Google Scholar
• von Scheele B, Mauskopf J, Brodtkorb TH, et al. Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2014;14:235–257.
   Web of Science ®Google Scholar
• Xie F, Zoratti M, Chan K, et al. Toward a centralized, systematic approach to the identification, appraisal, and use of health state utility values for reimbursement decision making: introducing the Health Utility Book (HUB). Med Decis Making. 2019;39(4):370–378.
   Web of Science ®Google Scholar
• Ara R, Wailoo AJ. NICE DSU technical support document 12: the use of health state utility values in decision models; 2011 [Last assessed on 2019 Apr 04]. Available from: http://www.nicedsu.org.uk
   Google Scholar